APO Research
Talk to an analyst

APO RESEARCH · REPORT

RNAi for Therapeutic

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

Selected research

Market Structure

Global RNAi for Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025190 pages

Choose your research edition.

Industry ResearchRNAi for Therapeutic Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal RNAi for Therapeutic Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal RNAi for Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNAi for Therapeutic Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal RNAi for Therapeutic Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.

US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.

Read the full market overview

In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.

Report Includes

This report provides an overview of the global RNAi for Therapeutic market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of RNAi for Therapeutic and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents RNAi for Therapeutic revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the RNAi for Therapeutic market size, projected growth trends, production technologies, key applications, and end-use industries.

RNAi for Therapeutic Segment by Company

Alnylam Pharmaceuticals

Arbutus Biopharma (Tekmira)

Arrowhead

Dicerna Pharmaceuticals

Mirna Therapeutics

Quark Pharmaceuticals

RXi Pharmaceuticals

Silence Therapeutics

Benitec Biopharma

miRagen Therapeutics

Sylentis

Gradalis

Sirnaomics

Silenseed

RNAi for Therapeutic Segment by Type

siRNA

miRNA

shRNA

RNAi for Therapeutic Segment by Application

Cancer

Cardiovascular

HBV

Others

RNAi for Therapeutic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNAi for Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNAi for Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNAi for Therapeutic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of RNAi for Therapeutic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global RNAi for Therapeutic industry.

Chapter 3: Detailed analysis of RNAi for Therapeutic companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, RNAi for Therapeuticrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of siRNA Table 3. Key Players of miRNA Table 4. Key Players of shRNA Table 4. Global RNAi for Therapeutic Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Cancer Table 6. Key Players of Cardiovascular Table 7. Key Players of HBV Table 8. Key Players of Others Table 9. Global RNAi for Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global RNAi for Therapeutic Market Size by Region (2021-2026) & (US$ Million) Table 11. Global RNAi for Therapeutic Market Share by Region (2021-2026) Table 12. Global RNAi for Therapeutic Market Size by Region (2027-2032) & (US$ Million) Table 13. Global RNAi for Therapeutic Market Share by Region (2027-2032) Table 14. RNAi for Therapeutic Industry Trends Table 15. RNAi for Therapeutic Industry Drivers Table 16. RNAi for Therapeutic Industry Opportunities and Challenges Table 17. RNAi for Therapeutic Industry Restraints Table 18. Global RNAi for Therapeutic Revenue by Company (US$ Million) & (2021-2026) Table 19. Global RNAi for Therapeutic Revenue Market Share by Company (2021-2026) Table 20. Global RNAi for Therapeutic Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global RNAi for Therapeutic Key Company Head Office and Area Served Table 22. Global RNAi for Therapeutic Company, Product Type & Application Table 23. Global RNAi for Therapeutic Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global RNAi for Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global RNAi for Therapeutic Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global RNAi for Therapeutic Market Size by Type (2021-2026) & (US$ Million) Table 28. Global RNAi for Therapeutic Market Size by Type (2027-2032) & (US$ Million) Table 29. Global RNAi for Therapeutic Revenue Market Share by Type (2021-2026) Table 30. Global RNAi for Therapeutic Revenue Market Share by Type (2027-2032) Table 31. Global RNAi for Therapeutic Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global RNAi for Therapeutic Market Size by Application (2021-2026) & (US$ Million) Table 33. Global RNAi for Therapeutic Market Size by Application (2027-2032) & (US$ Million) Table 34. Global RNAi for Therapeutic Revenue Market Share by Application (2021-2026) Table 35. Global RNAi for Therapeutic Revenue Market Share by Application (2027-2032) Table 36. Alnylam Pharmaceuticals Company Information Table 37. Alnylam Pharmaceuticals Business Overview Table 38. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Alnylam Pharmaceuticals RNAi for Therapeutic Product Portfolio Table 40. Alnylam Pharmaceuticals Recent Development Table 41. Arbutus Biopharma (Tekmira) Company Information Table 42. Arbutus Biopharma (Tekmira) Business Overview Table 43. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product Portfolio Table 45. Arbutus Biopharma (Tekmira) Recent Development Table 46. Arrowhead Company Information Table 47. Arrowhead Business Overview Table 48. Arrowhead RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Arrowhead RNAi for Therapeutic Product Portfolio Table 50. Arrowhead Recent Development Table 51. Dicerna Pharmaceuticals Company Information Table 52. Dicerna Pharmaceuticals Business Overview Table 53. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Dicerna Pharmaceuticals RNAi for Therapeutic Product Portfolio Table 55. Dicerna Pharmaceuticals Recent Development Table 56. Mirna Therapeutics Company Information Table 57. Mirna Therapeutics Business Overview Table 58. Mirna Therapeutics RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Mirna Therapeutics RNAi for Therapeutic Product Portfolio Table 60. Mirna Therapeutics Recent Development Table 61. Quark Pharmaceuticals Company Information Table 62. Quark Pharmaceuticals Business Overview Table 63. Quark Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Quark Pharmaceuticals RNAi for Therapeutic Product Portfolio Table 65. Quark Pharmaceuticals Recent Development Table 66. RXi Pharmaceuticals Company Information Table 67. RXi Pharmaceuticals Business Overview Table 68. RXi Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. RXi Pharmaceuticals RNAi for Therapeutic Product Portfolio Table 70. RXi Pharmaceuticals Recent Development Table 71. Silence Therapeutics Company Information Table 72. Silence Therapeutics Business Overview Table 73. Silence Therapeutics RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Silence Therapeutics RNAi for Therapeutic Product Portfolio Table 75. Silence Therapeutics Recent Development Table 76. Benitec Biopharma Company Information Table 77. Benitec Biopharma Business Overview Table 78. Benitec Biopharma RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Benitec Biopharma RNAi for Therapeutic Product Portfolio Table 80. Benitec Biopharma Recent Development Table 81. miRagen Therapeutics Company Information Table 82. miRagen Therapeutics Business Overview Table 83. miRagen Therapeutics RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. miRagen Therapeutics RNAi for Therapeutic Product Portfolio Table 85. miRagen Therapeutics Recent Development Table 86. Sylentis Company Information Table 87. Sylentis Business Overview Table 88. Sylentis RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Sylentis RNAi for Therapeutic Product Portfolio Table 90. Sylentis Recent Development Table 91. Gradalis Company Information Table 92. Gradalis Business Overview Table 93. Gradalis RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. Gradalis RNAi for Therapeutic Product Portfolio Table 95. Gradalis Recent Development Table 96. Sirnaomics Company Information Table 97. Sirnaomics Business Overview Table 98. Sirnaomics RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 99. Sirnaomics RNAi for Therapeutic Product Portfolio Table 100. Sirnaomics Recent Development Table 101. Silenseed Company Information Table 102. Silenseed Business Overview Table 103. Silenseed RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 104. Silenseed RNAi for Therapeutic Product Portfolio Table 105. Silenseed Recent Development Table 106. North America RNAi for Therapeutic Market Size by Type (2021-2026) & (US$ Million) Table 107. North America RNAi for Therapeutic Market Size by Type (2027-2032) & (US$ Million) Table 108. North America RNAi for Therapeutic Market Size by Application (2021-2026) & (US$ Million) Table 109. North America RNAi for Therapeutic Market Size by Application (2027-2032) & (US$ Million) Table 110. North America RNAi for Therapeutic Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. North America RNAi for Therapeutic Market Size by Country (2021-2026) Table 112. North America RNAi for Therapeutic Market Size by Country (2027-2032) Table 113. Europe RNAi for Therapeutic Market Size by Type (2021-2026) & (US$ Million) Table 114. Europe RNAi for Therapeutic Market Size by Type (2027-2032) & (US$ Million) Table 115. Europe RNAi for Therapeutic Market Size by Application (2021-2026) & (US$ Million) Table 116. Europe RNAi for Therapeutic Market Size by Application (2027-2032) & (US$ Million) Table 117. Europe RNAi for Therapeutic Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Europe RNAi for Therapeutic Market Size by Country (2021-2026) Table 119. Europe RNAi for Therapeutic Market Size by Country (2027-2032) Table 120. China RNAi for Therapeutic Market Size by Type (2021-2026) & (US$ Million) Table 121. China RNAi for Therapeutic Market Size by Type (2027-2032) & (US$ Million) Table 122. China RNAi for Therapeutic Market Size by Application (2021-2026) & (US$ Million) Table 123. China RNAi for Therapeutic Market Size by Application (2027-2032) & (US$ Million) Table 124. Asia RNAi for Therapeutic Market Size by Type (2021-2026) & (US$ Million) Table 125. Asia RNAi for Therapeutic Market Size by Type (2027-2032) & (US$ Million) Table 126. Asia RNAi for Therapeutic Market Size by Application (2021-2026) & (US$ Million) Table 127. Asia RNAi for Therapeutic Market Size by Application (2027-2032) & (US$ Million) Table 128. Asia RNAi for Therapeutic Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. Asia RNAi for Therapeutic Market Size by Country (2021-2026) Table 130. Asia RNAi for Therapeutic Market Size by Country (2027-2032) Table 131. South America, Middle East & Africa RNAi for Therapeutic Market Size by Type (2021-2026) & (US$ Million) Table 132. South America, Middle East & Africa RNAi for Therapeutic Market Size by Type (2027-2032) & (US$ Million) Table 133. South America, Middle East & Africa RNAi for Therapeutic Market Size by Application (2021-2026) & (US$ Million) Table 134. South America, Middle East & Africa RNAi for Therapeutic Market Size by Application (2027-2032) & (US$ Million) Table 135. South America, Middle East & Africa RNAi for Therapeutic Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. South America, Middle East & Africa RNAi for Therapeutic Market Size by Country (2021-2026) Table 137. South America, Middle East & Africa RNAi for Therapeutic Market Size by Country (2027-2032) Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. RNAi for Therapeutic Product Image Figure 2. Global RNAi for Therapeutic Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global RNAi for Therapeutic Market Share by Type: 2025 VS 2032 Figure 4. siRNA Image Figure 5. miRNA Image Figure 6. shRNA Image Figure 7. Global RNAi for Therapeutic Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global RNAi for Therapeutic Market Share by Application: 2025 VS 2032 Figure 9. Cancer Image Figure 10. Cardiovascular Image Figure 11. HBV Image Figure 12. Others Image Figure 13. Global RNAi for Therapeutic Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 15. Global RNAi for Therapeutic Market Share by Region: 2025 VS 2032 Figure 16. Years Considered Figure 17. Global RNAi for Therapeutic Market Share by Players in 2025 Figure 18. Global Top 5 and 10 RNAi for Therapeutic Players Market Share by Revenue in 2025 Figure 19. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global RNAi for Therapeutic Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global RNAi for Therapeutic Revenue Market Share by Type (2021-2032) Figure 22. Global RNAi for Therapeutic Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global RNAi for Therapeutic Revenue Market Share by Application (2021-2032) Figure 24. North America RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 25. North America RNAi for Therapeutic Market Share by Type (2021-2032) Figure 26. North America RNAi for Therapeutic Market Share by Application (2021-2032) Figure 27. North America RNAi for Therapeutic Market Share by Country (2021-2032) Figure 28. United States RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 29. Canada RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 30. Mexico RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 31. Europe RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 32. Europe RNAi for Therapeutic Market Share by Type (2021-2032) Figure 33. Europe RNAi for Therapeutic Market Share by Application (2021-2032) Figure 34. Europe RNAi for Therapeutic Market Share by Country (2021-2032) Figure 35. Germany RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 36. France RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 37. U.K. RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 38. Italy RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 39. Russia RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 40. Nordic Countries RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 41. China RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 42. China RNAi for Therapeutic Market Share by Type (2021-2032) Figure 43. China RNAi for Therapeutic Market Share by Application (2021-2032) Figure 44. Asia RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 45. Asia RNAi for Therapeutic Market Share by Type (2021-2032) Figure 46. Asia RNAi for Therapeutic Market Share by Application (2021-2032) Figure 47. Asia RNAi for Therapeutic Market Share by Country (2021-2032) Figure 48. Japan RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 49. South Korea RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 50. Taiwan RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 51. Southeast Asia RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 52. India RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 53. Australia RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa RNAi for Therapeutic Market Share by Type (2021-2032) Figure 56. South America, Middle East & Africa RNAi for Therapeutic Market Share by Application (2021-2032) Figure 57. South America, Middle East & Africa RNAi for Therapeutic Market Share by Country (2021-2032) Figure 58. Brazil RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 59. South Africa RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 60. Saudi Arabia RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 61. Turkey RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 62. Argentina RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 63. UAE RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 64. Egypt RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 65. Chile RNAi for Therapeutic Market Size (2021-2032) & (US$ Million) Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • siRNA
  • miRNA
  • shRNA
Applications
  • Cancer
  • Cardiovascular
  • HBV
  • Others
Companies covered
  • Alnylam Pharmaceuticals
  • Arbutus Biopharma (Tekmira)
  • Arrowhead
  • Dicerna Pharmaceuticals
  • Mirna Therapeutics
  • Quark Pharmaceuticals
  • RXi Pharmaceuticals
  • Silence Therapeutics
  • Benitec Biopharma
  • miRagen Therapeutics
  • Sylentis
  • Gradalis
  • Sirnaomics
  • Silenseed

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global RNAi for Therapeutic Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 siRNA
  5. 1.2.3 miRNA
  6. 1.2.4 shRNA
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global RNAi for Therapeutic Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Cancer
  10. 1.3.3 Cardiovascular
  11. 1.3.4 HBV
  12. 1.3.5 Others
  13. 1.4 Global Market Growth Prospects
  14. 1.5 Global RNAi for Therapeutic Growth Trends by Region
  15. 1.5.1 Global RNAi for Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
  16. 1.5.2 RNAi for Therapeutic Market Size by Region (2021-2026)
  17. 1.5.3 RNAi for Therapeutic Market Size by Region (2027-2032)
  18. 1.6 Assumptions and Limitations
  19. 1.7 Study Goals and Objectives
  20. 1.8 Years Considered
2 Global RNAi for Therapeutic Market Dynamics
  1. 2.1 RNAi for Therapeutic Industry Trends
  2. 2.2 RNAi for Therapeutic Industry Drivers
  3. 2.3 RNAi for Therapeutic Industry Opportunities and Challenges
  4. 2.4 RNAi for Therapeutic Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global RNAi for Therapeutic Revenue by Company (2021-2026)
  2. 3.2 Global RNAi for Therapeutic Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global RNAi for Therapeutic Key Company Head office and Area Served
  4. 3.4 Global RNAi for Therapeutic Company, Product Type & Application
  5. 3.5 Global RNAi for Therapeutic Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global RNAi for Therapeutic Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 RNAi for Therapeutic Players Market Share by Revenue in 2025
  9. 3.6.3 2025 RNAi for Therapeutic Tier 1, Tier 2, and Tier 3
4 RNAi for Therapeutic Market by Type
  1. 4.1 Global RNAi for Therapeutic Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global RNAi for Therapeutic Market Size by Type (2021-2032)
  3. 4.3 Global RNAi for Therapeutic Market Size Share by Type (2021-2032)
5 RNAi for Therapeutic Market by Application
  1. 5.1 Global RNAi for Therapeutic Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global RNAi for Therapeutic Market Size by Application (2021-2032)
  3. 5.3 Global RNAi for Therapeutic Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Alnylam Pharmaceuticals
  2. 6.1.1 Alnylam Pharmaceuticals Company Information
  3. 6.1.2 Alnylam Pharmaceuticals Business Overview
  4. 6.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Product Portfolio
  6. 6.1.5 Alnylam Pharmaceuticals Recent Developments
  7. 6.2 Arbutus Biopharma (Tekmira)
  8. 6.2.1 Arbutus Biopharma (Tekmira) Company Information
  9. 6.2.2 Arbutus Biopharma (Tekmira) Business Overview
  10. 6.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product Portfolio
  12. 6.2.5 Arbutus Biopharma (Tekmira) Recent Developments
  13. 6.3 Arrowhead
  14. 6.3.1 Arrowhead Company Information
  15. 6.3.2 Arrowhead Business Overview
  16. 6.3.3 Arrowhead RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Arrowhead RNAi for Therapeutic Product Portfolio
  18. 6.3.5 Arrowhead Recent Developments
  19. 6.4 Dicerna Pharmaceuticals
  20. 6.4.1 Dicerna Pharmaceuticals Company Information
  21. 6.4.2 Dicerna Pharmaceuticals Business Overview
  22. 6.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Product Portfolio
  24. 6.4.5 Dicerna Pharmaceuticals Recent Developments
  25. 6.5 Mirna Therapeutics
  26. 6.5.1 Mirna Therapeutics Company Information
  27. 6.5.2 Mirna Therapeutics Business Overview
  28. 6.5.3 Mirna Therapeutics RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Mirna Therapeutics RNAi for Therapeutic Product Portfolio
  30. 6.5.5 Mirna Therapeutics Recent Developments
  31. 6.6 Quark Pharmaceuticals
  32. 6.6.1 Quark Pharmaceuticals Company Information
  33. 6.6.2 Quark Pharmaceuticals Business Overview
  34. 6.6.3 Quark Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Quark Pharmaceuticals RNAi for Therapeutic Product Portfolio
  36. 6.6.5 Quark Pharmaceuticals Recent Developments
  37. 6.7 RXi Pharmaceuticals
  38. 6.7.1 RXi Pharmaceuticals Company Information
  39. 6.7.2 RXi Pharmaceuticals Business Overview
  40. 6.7.3 RXi Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 RXi Pharmaceuticals RNAi for Therapeutic Product Portfolio
  42. 6.7.5 RXi Pharmaceuticals Recent Developments
  43. 6.8 Silence Therapeutics
  44. 6.8.1 Silence Therapeutics Company Information
  45. 6.8.2 Silence Therapeutics Business Overview
  46. 6.8.3 Silence Therapeutics RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Silence Therapeutics RNAi for Therapeutic Product Portfolio
  48. 6.8.5 Silence Therapeutics Recent Developments
  49. 6.9 Benitec Biopharma
  50. 6.9.1 Benitec Biopharma Company Information
  51. 6.9.2 Benitec Biopharma Business Overview
  52. 6.9.3 Benitec Biopharma RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Benitec Biopharma RNAi for Therapeutic Product Portfolio
  54. 6.9.5 Benitec Biopharma Recent Developments
  55. 6.10 miRagen Therapeutics
  56. 6.10.1 miRagen Therapeutics Company Information
  57. 6.10.2 miRagen Therapeutics Business Overview
  58. 6.10.3 miRagen Therapeutics RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 miRagen Therapeutics RNAi for Therapeutic Product Portfolio
  60. 6.10.5 miRagen Therapeutics Recent Developments
  61. 6.11 Sylentis
  62. 6.11.1 Sylentis Company Information
  63. 6.11.2 Sylentis Business Overview
  64. 6.11.3 Sylentis RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Sylentis RNAi for Therapeutic Product Portfolio
  66. 6.11.5 Sylentis Recent Developments
  67. 6.12 Gradalis
  68. 6.12.1 Gradalis Company Information
  69. 6.12.2 Gradalis Business Overview
  70. 6.12.3 Gradalis RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Gradalis RNAi for Therapeutic Product Portfolio
  72. 6.12.5 Gradalis Recent Developments
  73. 6.13 Sirnaomics
  74. 6.13.1 Sirnaomics Company Information
  75. 6.13.2 Sirnaomics Business Overview
  76. 6.13.3 Sirnaomics RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Sirnaomics RNAi for Therapeutic Product Portfolio
  78. 6.13.5 Sirnaomics Recent Developments
  79. 6.14 Silenseed
  80. 6.14.1 Silenseed Company Information
  81. 6.14.2 Silenseed Business Overview
  82. 6.14.3 Silenseed RNAi for Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Silenseed RNAi for Therapeutic Product Portfolio
  84. 6.14.5 Silenseed Recent Developments
7 North America
  1. 7.1 North America RNAi for Therapeutic Market Size (2021-2032)
  2. 7.2 North America RNAi for Therapeutic Market Size by Type
  3. 7.2.1 North America RNAi for Therapeutic Market Size by Type (2021-2026)
  4. 7.2.2 North America RNAi for Therapeutic Market Size by Type (2027-2032)
  5. 7.2.3 North America RNAi for Therapeutic Market Share by Type (2021-2032)
  6. 7.3 North America RNAi for Therapeutic Market Size by Application
  7. 7.3.1 North America RNAi for Therapeutic Market Size by Application (2021-2026)
  8. 7.3.2 North America RNAi for Therapeutic Market Size by Application (2027-2032)
  9. 7.3.3 North America RNAi for Therapeutic Market Share by Application (2021-2032)
  10. 7.4 North America RNAi for Therapeutic Market Size by Country
  11. 7.4.1 North America RNAi for Therapeutic Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America RNAi for Therapeutic Market Size by Country (2021-2026)
  13. 7.4.3 North America RNAi for Therapeutic Market Size by Country (2027-2032)
  14. 7.4.4 North America RNAi for Therapeutic Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe RNAi for Therapeutic Market Size (2021-2032)
  2. 8.2 Europe RNAi for Therapeutic Market Size by Type
  3. 8.2.1 Europe RNAi for Therapeutic Market Size by Type (2021-2026)
  4. 8.2.2 Europe RNAi for Therapeutic Market Size by Type (2027-2032)
  5. 8.2.3 Europe RNAi for Therapeutic Market Share by Type (2021-2032)
  6. 8.3 Europe RNAi for Therapeutic Market Size by Application
  7. 8.3.1 Europe RNAi for Therapeutic Market Size by Application (2021-2026)
  8. 8.3.2 Europe RNAi for Therapeutic Market Size by Application (2027-2032)
  9. 8.3.3 Europe RNAi for Therapeutic Market Share by Application (2021-2032)
  10. 8.4 Europe RNAi for Therapeutic Market Size by Country
  11. 8.4.1 Europe RNAi for Therapeutic Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe RNAi for Therapeutic Market Size by Country (2021-2026)
  13. 8.4.3 Europe RNAi for Therapeutic Market Size by Country (2027-2032)
  14. 8.4.4 Europe RNAi for Therapeutic Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China RNAi for Therapeutic Market Size (2021-2032)
  2. 9.2 China RNAi for Therapeutic Market Size by Type
  3. 9.2.1 China RNAi for Therapeutic Market Size by Type (2021-2026)
  4. 9.2.2 China RNAi for Therapeutic Market Size by Type (2027-2032)
  5. 9.2.3 China RNAi for Therapeutic Market Share by Type (2021-2032)
  6. 9.3 China RNAi for Therapeutic Market Size by Application
  7. 9.3.1 China RNAi for Therapeutic Market Size by Application (2021-2026)
  8. 9.3.2 China RNAi for Therapeutic Market Size by Application (2027-2032)
  9. 9.3.3 China RNAi for Therapeutic Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia RNAi for Therapeutic Market Size (2021-2032)
  2. 10.2 Asia RNAi for Therapeutic Market Size by Type
  3. 10.2.1 Asia RNAi for Therapeutic Market Size by Type (2021-2026)
  4. 10.2.2 Asia RNAi for Therapeutic Market Size by Type (2027-2032)
  5. 10.2.3 Asia RNAi for Therapeutic Market Share by Type (2021-2032)
  6. 10.3 Asia RNAi for Therapeutic Market Size by Application
  7. 10.3.1 Asia RNAi for Therapeutic Market Size by Application (2021-2026)
  8. 10.3.2 Asia RNAi for Therapeutic Market Size by Application (2027-2032)
  9. 10.3.3 Asia RNAi for Therapeutic Market Share by Application (2021-2032)
  10. 10.4 Asia RNAi for Therapeutic Market Size by Country
  11. 10.4.1 Asia RNAi for Therapeutic Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia RNAi for Therapeutic Market Size by Country (2021-2026)
  13. 10.4.3 Asia RNAi for Therapeutic Market Size by Country (2027-2032)
  14. 10.4.4 Asia RNAi for Therapeutic Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa RNAi for Therapeutic Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa RNAi for Therapeutic Market Size by Type
  3. 11.2.1 South America, Middle East & Africa RNAi for Therapeutic Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa RNAi for Therapeutic Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa RNAi for Therapeutic Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa RNAi for Therapeutic Market Size by Application
  7. 11.3.1 South America, Middle East & Africa RNAi for Therapeutic Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa RNAi for Therapeutic Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa RNAi for Therapeutic Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa RNAi for Therapeutic Market Size by Country
  11. 11.4.1 South America, Middle East & Africa RNAi for Therapeutic Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa RNAi for Therapeutic Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa RNAi for Therapeutic Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa RNAi for Therapeutic Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst